Target Development and Commercialization Plan Clause Samples

The Target Development and Commercialization Plan clause outlines the requirements and expectations for how a specific product or technology will be developed and brought to market. Typically, this clause details the milestones, timelines, and responsibilities of each party involved in the development process, and may require regular updates or approvals of the plan. Its core function is to ensure both parties have a clear, shared understanding of the steps and standards for progressing from development to commercialization, thereby reducing misunderstandings and aligning efforts toward successful product launch.
Target Development and Commercialization Plan. In addition to the above general diligence requirements, KI PHARMA shall meet the target development and commercialization plan for Venture Products. The target development and commercialization plan for the BNP7787 Products is set forth in Attachment D hereto, and those for the other Venture Products shall be decided by the parties hereto as soon as reasonably practical. These target development and commercialization plans will be updated on a semi-annual basis by the Steering Committee. If any of the specified targets are not met with respect to a particular Venture Product, and such targets continue to remain unmet for a period of 60 days or greater following notice to the parties by any party hereunder, then the parties hereto shall discuss and decide in good faith how to solve the problem. If (a) the specified development performance targets as defined by the Steering Committee for any particular Venture Product are not met on an annual basis for three consecutive years, or (b) such product does not receive Government Regulatory Approval to sell and distribute such product in the Territory within 10 years of the date of this Agreement or conveyance of a product to the Venture, then all licenses granted hereunder to such Venture Product, and to the Improvements, Patent Rights, and Know-How provided by GRELAN or BIONUMERIK with respect to such product shall terminate, and all right, title, and interest in such Venture Product shall revert to the party or parties who granted such rights to the Venture Product(s), provided that such rights shall not revert to a party if the failure to meet such target was caused in substantial part by the actions or failure to act of such party. An extension of the time to meet the development performance requirements in the previous sentence may be granted upon mutual agreement between GRELAN and BIONUMERIK.
View SourceView Similar (2)
Target Development and Commercialization Plan. In addition to the above general diligence requirements, ASTA Medica shall meet the Development Plan targets determined by the Alliance Steering Committee for the Product(s). [**]. An extension of the time to meet the development performance requirements in the previous sentence may be granted upon mutual agreement between ASTA Medica and BioNumerik.
View SourceView Similar (2)
Target Development and Commercialization Plan. In addition to the above general diligence requirements, ASTA Medica shall meet the Development Plan targets determined by the Alliance Steering Committee for the Product(s). If any of the specified targets are not met with respect to the Product(s), and such targets continue to remain unmet for a period of 60 days or greater following notice to ASTA Medica by BioNumerik, then the Parties hereto shall discuss and decide in good faith how to solve the problem. If (a) the specified development and commercialization targets contained in the Development Plan and determined by the Alliance Steering Committee for the Product(s) are not met on an annual basis for three consecutive years, (b) the Product(s) does not receive Government Regulatory Approval to sell and distribute such product in at least one country in Europe within 4 years after the date of this Agreement, or (c) ASTA Medica completely ceases development, marketing, or regulatory activity with respect to the Product(s) in one or more countries in the Territory and such cessation continues for more than 60 days, then all licenses granted by BioNumerik hereunder, and to the BioNumerik Improvements, BioNumerik Patent Rights, and BioNumerik Know-How shall terminate (either for the entire Territory with respect to clause(a) or clause(b) of this sentence or on a country by country basis with respect to clause(c) of this sentence), all right, title, and interest in the Product(s) shall automatically revert to BioNumerik (either for the entire Territory with respect to clause(a) or clause(b) of this sentence or on a country by country basis with respect to clause(c) of this sentence), and all transferable elements of government approvals, registrations or other regulatory approvals and applications shall be promptly transferred to BioNumerik, provided that such rights shall not revert to BioNumerik if the failure to meet such target, take such action, or receive such approval, as the case may be, was caused in substantial part by the actions or failure to act of BioNumerik. An extension of the time to meet the development performance requirements in the previous sentence may be granted upon mutual agreement between ASTA Medica and BioNumerik.
View SourceView Similar (2)
Target Development and Commercialization Plan. In addition to the above general diligence requirements, KI PHARMA shall meet the target development and commercialization plan for Venture Products. The target development and commercialization plan for the BNP7787 Products is set forth in Attachment D hereto, and those for the other Venture Products shall be decided by the parties hereto as soon as reasonably practical. These target development and commercialization plans will be updated on a semi-annual basis by the Steering Committee. If any of the specified targets are not met with respect to a particular Venture Product, and such targets continue to remain unmet for a period of [**] or greater following notice to the parties by any party hereunder, then the parties hereto shall discuss and decide in good faith how to solve the problem. [**]. An extension of the time to meet the development performance requirements in the previous sentence may be granted upon mutual agreement between GRELAN and BIONUMERIK.
View SourceView Similar (2)

Related to Target Development and Commercialization Plan

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Commercialization Plan On a Product by Product basis, not later than sixty (60) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory, the MSC shall prepare and approve a rolling multiyear (not less than three (3) years) plan for Commercializing such Product in the Copromotion Territory (the "Copromotion Territory Commercialization Plan"), which plan includes a comprehensive market development, marketing, sales, supply and distribution strategy for such Product in the Copromotion Territory. The Copromotion Territory Commercialization Plan shall be updated by the MSC at least once each calendar year such that it addresses no less than the three (3) upcoming years. Not later than thirty (30) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory and thereafter on or before September 30 of each calendar year, the MSC shall prepare an annual commercialization plan and budget (the "Annual Commercialization Plan and Budget"), which plan is based on the then current Copromotion Territory Commercialization Plan and includes a comprehensive market development, marketing, sales, supply and distribution strategy, including an overall budget for anticipated marketing, promotion and sales efforts in the upcoming calendar year (the first such Annual Development Plan and Budget shall cover the remainder of the calendar year in which such Product is anticipated to be approved plus the first full calendar year thereafter). The Annual Commercialization Plan and Budget will specify which Target Markets and distribution channels each Party shall devote its respective Promotion efforts towards, the personnel and other resources to be devoted by each Party to such efforts, the number and positioning of Details to be performed by each Party, as well as market and sales forecasts and related operating expenses, for the Product in each country of the Copromotion Territory, and budgets for projected Pre-Marketing Expenses, Sales and Marketing Expenses and Post-Approval Research and Regulatory Expenses. In preparing and updating the Copromotion Territory Commercialization Plan and each Annual Commercialization Plan and Budget, the MSC will take into consideration factors such as market conditions, regulatory issues and competition.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones) B. Estimated total development time

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.